DK1129191T3 - Fremgangsmåder til diagnosticering eller behandling af neurologiske sygdomme - Google Patents

Fremgangsmåder til diagnosticering eller behandling af neurologiske sygdomme

Info

Publication number
DK1129191T3
DK1129191T3 DK99960975T DK99960975T DK1129191T3 DK 1129191 T3 DK1129191 T3 DK 1129191T3 DK 99960975 T DK99960975 T DK 99960975T DK 99960975 T DK99960975 T DK 99960975T DK 1129191 T3 DK1129191 T3 DK 1129191T3
Authority
DK
Denmark
Prior art keywords
diagnosing
methods
neurological diseases
treating neurological
treating
Prior art date
Application number
DK99960975T
Other languages
English (en)
Inventor
Roger Nitsch
Isabell Greeve
Original Assignee
Evotec Neurosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences Gmbh filed Critical Evotec Neurosciences Gmbh
Application granted granted Critical
Publication of DK1129191T3 publication Critical patent/DK1129191T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
DK99960975T 1998-11-12 1999-11-12 Fremgangsmåder til diagnosticering eller behandling af neurologiske sygdomme DK1129191T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98121478A EP1002862A1 (en) 1998-11-12 1998-11-12 Methods of diagnosing or treating neurological diseases

Publications (1)

Publication Number Publication Date
DK1129191T3 true DK1129191T3 (da) 2006-07-17

Family

ID=8232965

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99960975T DK1129191T3 (da) 1998-11-12 1999-11-12 Fremgangsmåder til diagnosticering eller behandling af neurologiske sygdomme

Country Status (8)

Country Link
US (2) US20050239169A1 (da)
EP (2) EP1002862A1 (da)
JP (1) JP4663121B2 (da)
AT (1) ATE321135T1 (da)
DE (1) DE69930545T2 (da)
DK (1) DK1129191T3 (da)
ES (1) ES2262352T3 (da)
WO (1) WO2000029569A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5810999A (en) * 1998-08-27 2000-03-21 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
NZ526617A (en) * 2000-11-28 2004-09-24 Wyeth Corp Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2002103017A1 (en) * 2001-05-31 2002-12-27 Chiba-Prefecture Nucleic acids isolated in neuroblastoma
AU2002324451A1 (en) 2001-06-21 2003-01-08 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
EP1513955A2 (en) * 2002-05-28 2005-03-16 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0814157A3 (en) * 1996-06-18 1998-01-07 Smithkline Beecham Corporation Diagnostic marker for variants of presenilin genes associated with Alzheimers Disease and Familial Adult Onset Alzheimers Disease
AU5810999A (en) * 1998-08-27 2000-03-21 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription

Also Published As

Publication number Publication date
US20050239169A1 (en) 2005-10-27
US20080261302A1 (en) 2008-10-23
DE69930545D1 (de) 2006-05-11
EP1129191B1 (en) 2006-03-22
JP4663121B2 (ja) 2011-03-30
DE69930545T2 (de) 2007-03-08
WO2000029569A1 (en) 2000-05-25
EP1129191A1 (en) 2001-09-05
ATE321135T1 (de) 2006-04-15
EP1002862A1 (en) 2000-05-24
ES2262352T3 (es) 2006-11-16
JP2002530076A (ja) 2002-09-17

Similar Documents

Publication Publication Date Title
FI973354A0 (fi) MAG-geenejä
DE3578190D1 (de) Test fuer nukleinsaeuresequenzen, insbesondere genetische veraenderungen.
CY1106978T1 (el) Ενζυμα φωσφοδιεστερασης
BR9912455A (pt) ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória
DK2256205T3 (da) Porphorymonas gingivalis-polypeptider og -polynukleotider
DK0920501T3 (da) Neuritin, et neurogen
DE69902796D1 (de) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
DK1108786T3 (da) Hidtil ukendt kollektin
DE69739071D1 (de) Menschliche tak1 und für diese kodierende dna
ATE321135T1 (de) Verfahren zur diagnose und behandlung neurologischer erkrankungen
NO942443D0 (no) Gen kodende for kationisk aminosyre transporter protein
EP0816498A3 (en) Excitatory amino acid receptor protein and related nucleic acid compounds
EP0911408A3 (en) DNA coding for serine/threonine kinase
ATE283356T1 (de) Tab1 protein und dafür kodierende dna
EE200100234A (et) PRV-1-geen ja selle kasutamine
DE69831584T2 (de) Polypeptide mit wasserkanalaktivität und dna sequenzen
EP1065269A4 (en) GENE CODING FOR HM1.24 AND PROMOTOR THEREOF
DE69943149D1 (en) Serinprotease bssp2
BR0107799A (pt) Proteìna de interação de wt1 wtip